These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1539695)

  • 1. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.
    Yao SK; McNatt J; Anderson HV; Eidt J; Cui KX; Golino P; Glas-Greenwalt P; Maraganore J; Buja LM; Willerson JT
    Am J Physiol; 1992 Feb; 262(2 Pt 2):H374-9. PubMed ID: 1539695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ; Prager NA; Sobel BE; Abendschein DR
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ; Stabilito IJ; Sitko GR; Polokoff MH
    Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
    Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
    Prager NA; Torr-Brown SR; Sobel BE; Abendschein DR
    J Am Coll Cardiol; 1993 Jul; 22(1):296-301. PubMed ID: 8509554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ; Connolly TM; York SJ; Bush LR
    Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K; Hornberger W
    Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR; Baum PK; Verhallen P; Eisenberg PR; Sullivan ME; Light DR
    J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis.
    Jackson CV; Wilson HC; Growe VG; Shuman RT; Gesellchen PD
    J Cardiovasc Pharmacol; 1993 Apr; 21(4):587-94. PubMed ID: 7681904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reocclusion after thrombolysis: a problem solved by hirudin?
    Rübsamen K; Eschenfelder V
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):97-100. PubMed ID: 1773004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.